{
    "Trade/Device Name(s)": [
        "Elecsys CA 15-3 II",
        "Elecsys Cancer Antigen 15-3 II"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K171605",
    "Predicate Device Reference 510(k) Number(s)": [
        "K001468"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI"
    ],
    "Summary Letter Date": "February 27, 2018",
    "Summary Letter Received Date": "June 1, 2017",
    "Submission Date": "May 26, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "CA 15-3"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Li-heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas e 801",
        "cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Quantitative detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys CA 15-3 II electrochemiluminescence immunoassay for quantitative determination of CA 15-3 in serum and Li-heparin plasma using cobas e platforms",
    "Indications for Use Summary": "Immunological in vitro assay for quantitative determination of CA 15-3 in human serum and Li-heparin plasma to aid in management of breast cancer patients, including early detection of recurrence and monitoring response to therapy in metastatic disease",
    "fda_folder": "Immunology"
}